2. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG. 1976; Direct stimulation of bone resorption by thyroid hormones. J Clin Invest. 58(3):529–34. DOI:
10.1172/JCI108497. PMID:
182721. PMCID:
PMC333209.
Article
3. Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K. 2004; Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol. 201(1):17–25. DOI:
10.1002/jcp.20041. PMID:
15281085.
Article
5. Vestergaard P, Mosekilde L. 2002; Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid. 12(5):411–9. DOI:
10.1089/105072502760043503. PMID:
12097203.
Article
6. Abrahamsen B, Jorgensen HL, Laulund AS, Nybo M, Bauer DC, Brix TH, et al. 2015; The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis. J Bone Miner Res. 30(5):898–905. DOI:
10.1002/jbmr.2416. PMID:
25431028.
Article
7. Ko YJ, Kim JY, Lee J, Song HJ, Kim JY, Choi NK, et al. 2014; Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health. 47(1):36–46. DOI:
10.3961/jpmph.2014.47.1.36. PMID:
24570805. PMCID:
PMC3930806.
Article
8. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. 1996; Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 81(12):4278–89. DOI:
10.1210/jcem.81.12.8954028. PMID:
8954028.
Article
10. Heemstra KA, Hamdy NA, Romijn JA, Smit JW. 2006; The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 16(6):583–91. DOI:
10.1089/thy.2006.16.583. PMID:
16839260.
Article
11. Cellini M, Rotondi M, Tanda ML, Piantanida E, Chiovato L, Beck-Peccoz P, et al. 2021; Skeletal health in patients with differentiated thyroid carcinoma. J Endocrinol Invest. 44(3):431–42. DOI:
10.1007/s40618-020-01359-6. PMID:
32696339.
Article
12. Notsu M, Yamauchi M, Morita M, Nawata K, Sugimoto T. 2020; Papillary thyroid carcinoma is a risk factor for severe osteoporosis. J Bone Miner Metab. 38(2):264–70. DOI:
10.1007/s00774-019-01053-5. PMID:
31664535.
Article
13. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2016; 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26(1):1–133. DOI:
10.1089/thy.2015.0020. PMID:
26462967. PMCID:
PMC4739132.
Article
15. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016; 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 26(10):1343–421. DOI:
10.1089/thy.2016.0229. PMID:
27521067.
Article
16. Carle A, Andersen SL, Boelaert K, Laurberg P. 2017; Management of endocrine disease: subclinical thyrotoxicosis: prevalence, causes and choice of therapy. Eur J Endocrinol. 176(6):R325–R37. DOI:
10.1530/EJE-16-0276. PMID:
28274949.
17. Chin SO, Ku CR, Kim BJ, Kim SW, Park KH, Song KH, et al. 2019; Medical treatment with somatostatin analogues in acromegaly: position statement. Endocrinol Metab (Seoul). 34(1):53–62. DOI:
10.3803/EnM.2019.34.1.53. PMID:
30912339. PMCID:
PMC6435847.
Article
18. Ku EJ, Kim KJ, Kim JH, Kim MK, Ahn CH, Lee KA, et al. 2021; Diagnosis for pheochromocytoma and paraganglioma: a joint position statement of the Korean pheochromocytoma and para-ganglioma task force. Endocrinol Metab (Seoul). 36(2):322–38. DOI:
10.3803/EnM.2020.908. PMID:
33820394. PMCID:
PMC8090459.
Article
20. Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz Sorensen N. 1977; Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenh). 85(3):515–25. DOI:
10.1530/acta.0.0850515. PMID:
577336.
Article
21. Bours SP, van Geel TA, Geusens PP, Janssen MJ, Janzing HM, Hoffland GA, et al. 2011; Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab. 96(5):1360–7. DOI:
10.1210/jc.2010-2135. PMID:
21411547.
Article
22. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. 2000; Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 15(8):1526–36. DOI:
10.1359/jbmr.2000.15.8.1526. PMID:
10934651.
Article
23. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Study of Osteoporotic Fractures Research Group. 2001; Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 134(7):561–8. DOI:
10.7326/0003-4819-134-7-200104030-00009. PMID:
12803168.
Article
24. Vestergaard P, Rejnmark L, Mosekilde L. 2005; Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int. 77(3):139–44. DOI:
10.1007/s00223-005-0068-x. PMID:
16151671.
Article
25. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. 1995; Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 332(12):767–73. DOI:
10.1056/NEJM199503233321202. PMID:
7862179.
28. Dhanwal DK, Gupta N. 2011; Bone mineral density trends in Indian patients with hyperthyroidism--effect of antithyroid therapy. J Assoc Physicians India. 59:561–2. PMID:
22334969.
30. Torgerson DJ, Campbell MK, Thomas RE, Reid DM. 1996; Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res. 11(2):293–7. DOI:
10.1002/jbmr.5650110219. PMID:
8822354.
Article
31. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. 2020; American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 26(Suppl 1):1–46. DOI:
10.4158/GL-2020-0524SUPPL. PMID:
32427503.
Article
32. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. 2020; Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 105(3):dgaa048. DOI:
10.1210/clinem/dgaa048. PMID:
32068863.
Article
33. Physician's guideline for osteoporosis. The Korean Society of Bone and Mineral Research 2020. DOI:
10.1210/clinem/dgaa048.
34. Udayakumar N, Chandrasekaran M, Rasheed MH, Suresh RV, Sivaprakash S. 2006; Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J. 47(11):947–50. PMID:
17075661.
35. Ale AO, Ogbera AO, Ebili HO, Adeyemo OL, Afe TO. 2018; Prevalence, predictive factors, and characteristics of osteoporosis in hyperthyroid patients. Int J Endocrinol. 2018:3540256. DOI:
10.1155/2018/3540256. PMID:
29849614. PMCID:
PMC5907485.
Article
36. Kuzma M, Vanuga P, Binkley N, Sagova I, Pavai D, Blazicek P, et al. 2018; High serum fractalkine is associated with lower trabecular bone score in premenopausal women with Graves' disease. Horm Metab Res. 50(8):609–14. DOI:
10.1055/a-0633-2814. PMID:
29954010.
Article
37. Boonya-Ussadorn T, Punkaew B, Sriassawaamorn N. 2010; A comparative study of bone mineral density between premenopausal women with hyperthyroidism and healthy premenopausal women. J Med Assoc Thai. 93 Suppl 6:S1–5. PMID:
21284134.
38. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. 1994; Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab. 78(4):955–9. DOI:
10.1210/jcem.78.4.8157727. PMID:
8157727.
Article
39. Harvey RD, McHardy KC, Reid IW, Paterson F, Bewsher PD, Duncan A, et al. 1991; Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab. 72(6):1189–94. DOI:
10.1210/jcem-72-6-1189. PMID:
2026741.
Article
40. Kisakol G, Kaya A, Gonen S, Tunc R. 2003; Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J. 50(6):657–61. DOI:
10.1507/endocrj.50.657. PMID:
14709834.
Article
41. Sabuncu T, Aksoy N, Arikan E, Ugur B, Tasan E, Hatemi H. Early changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidism. Endocr Res. 2001; 27(1-2):203–13. DOI:
10.1081/ERC-100107181. PMID:
11428712.
Article
42. Olkawa M, Kushida K, Takahashi M, Ohishi T, Hoshino H, Suzuki M, et al. 1999; Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol (Oxf). 50(2):171–6. DOI:
10.1046/j.1365-2265.1999.00626.x. PMID:
10396358.
Article
43. Karunakaran P, Maharajan C, Mohamed KN, Rachamadugu SV. 2016; Rapid restoration of bone mass after surgical management of hyperthyroidism: a prospective case control study in Southern India. Surgery. 159(3):771–6. DOI:
10.1016/j.surg.2015.10.002. PMID:
26582500.
Article
44. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, et al. 2000; Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab. 85(11):4157–61. DOI:
10.1210/jcem.85.11.6979. PMID:
11095447.
Article
45. Zhong N, Xu B, Cui R, Xu M, Su J, Zhang Z, et al. 2016; Positive correlation between serum osteocalcin and testosterone in male hyperthyroidism patients with high bone turnover. Exp Clin Endocrinol Diabetes. 124(7):452–6. DOI:
10.1055/s-0042-107944. PMID:
27219888.
Article
46. Ock SY, Chung YS, Choi YJ. 2016; Changes in bone mineral density and trabecular bone score in Graves' disease patients after anti-thyroid therapy. Osteoporos Sarcopenia. 2(3):175–9. DOI:
10.1016/j.afos.2016.05.004. PMID:
30775484. PMCID:
PMC6372732.
Article
47. Nicolaisen P, Obling ML, Winther KH, Hansen S, Hermann AP, Hegedus L, et al. 2021; Consequences of hyperthyroidism and its treatment for bone microarchitecture assessed by high-resolution peripheral quantitative computed tomography. Thyroid. 31(2):208–16. DOI:
10.1089/thy.2020.0084. PMID:
32703114.
Article
48. Kim KM, Choi SH, Lim S, Moon JH, Kim JH, Kim SW, et al. 2014; Interactions between dietary calcium intake and bone mineral density or bone geometry in a low calcium intake population (KNHANES IV 2008-2010). J Clin Endocrinol Metab. 99(7):2409–17. DOI:
10.1210/jc.2014-1006. PMID:
24684465.
Article
49. Park JH, Hong IY, Chung JW, Choi HS. 2018; Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore). 97(26):e11032. DOI:
10.1097/MD.0000000000011032. PMID:
29952942. PMCID:
PMC6242298.
50. Lupoli G, Nuzzo V, Di Carlo C, Affinito P, Vollery M, Vitale G, et al. 1996; Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecol Endocrinol. 10(5):343–8. DOI:
10.3109/09513599609012821. PMID:
8915664.
Article
51. Lupoli GA, Fittipaldi MR, Fonderico F, Panico A, Colarusso S, Di Micco L, et al. 2005; Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients. Minerva Endocrinol. 30(2):89–94. PMID:
15988404.
52. Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, et al. 2006; Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab. 24(2):105–13. DOI:
10.1007/s00774-005-0655-y. PMID:
16502116.
Article
53. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. 2011; Interpretation and use of FRAX in clinical practice. Osteoporos Int. 22(9):2395–411. DOI:
10.1007/s00198-011-1713-z. PMID:
21779818.
Article
55. Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, et al. 2004; High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone. 35(3):785–91. DOI:
10.1016/j.bone.2004.04.021. PMID:
15336617.
Article
56. Gürlek A, Gedik O. 1999; Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid. 9(6):539–43. DOI:
10.1089/thy.1999.9.539. PMID:
10411115.
Article
57. Tauchmanovà L, Nuzzo V, Del Puente A, Fonderico F, Esposito-Del Puente A, Padulla S, et al. 2004; Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas. 48(3):299–306. DOI:
10.1016/j.maturitas.2004.02.017. PMID:
15207896.
Article
58. Lee WY, Oh KW, Rhee EJ, Jung CH, Kim SW, Yun EJ, et al. 2006; Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res. 37(4):511–6. DOI:
10.1016/j.arcmed.2005.09.009. PMID:
16624651.
Article
60. Földes J, Tarján G, Szathmari M, Varga F, Krasznai I, Horvath C. 1993; Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol (Oxf). 39(5):521–7. DOI:
10.1111/j.1365-2265.1993.tb02403.x. PMID:
8252739.
Article
61. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedüs L, Siersbaek-Nielsen K. 1998; Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf). 48(3):285–90. DOI:
10.1046/j.1365-2265.1998.00427.x. PMID:
9578817.
Article
62. Yan Z, Huang H, Li J, Wang J. 2016; Relationship between subclinical thyroid dysfunction and the risk of fracture: a meta-analysis of prospective cohort studies. Osteoporos Int. 27(1):115–25. DOI:
10.1007/s00198-015-3221-z. PMID:
26223189.
Article
63. Saler T, Ahbab S, Sağlam ZA, Keşkek ŞÖ, Kurnaz S. 2014; Endogenous subclinical hyperthyroidism may not lead to bone loss in premenopausal women. Hippokratia. 18(3):240–4.
64. Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. 2012; The skeletal consequences of thyrotoxicosis. J Endocrinol. 213(3):209–21. DOI:
10.1530/JOE-12-0059. PMID:
22454529.
Article
66. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. 2015; Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 313(20):2055–65. DOI:
10.1001/jama.2015.5161. PMID:
26010634. PMCID:
PMC4729304.
67. Wirth CD, Blum MR, da Costa BR, Baumgartner C, Collet TH, Medici M, et al. 2014; Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis. Ann Intern Med. 161(3):189–99. DOI:
10.7326/M14-0125. PMID:
25089863. PMCID:
PMC4403766.
Article
68. Kung AW, Yeung SS. 1996; Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab. 81(3):1232–6. DOI:
10.1210/jc.81.3.1232. PMID:
8772604.
Article
69. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al. 2005; Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 365(9471):1621–8. DOI:
10.1016/S0140-6736(05)63013-9. PMID:
15885294.
Article
70. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. 2007; Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 370(9588):657–66. DOI:
10.1016/S0140-6736(07)61342-7.
Article
72. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2009; (2):CD000227. DOI:
10.1002/14651858.CD000227.pub3. PMID:
16034849.
Article
74. Rosen HN, Moses AC, Gundberg C, Kung VT, Seyedin SM, Chen T, et al. 1993; Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab. 77(3):664–9. DOI:
10.1210/jcem.77.3.8370687. PMID:
8370687.
Article
75. Faber J, Galløe AM. 1994; Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 130(4):350–6. DOI:
10.1530/eje.0.1300350. PMID:
8162163.
Article
77. Yoon BH, Lee Y, Oh HJ, Kim SH, Lee YK. 2019; Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. J Bone Metab. 26(1):51–60. DOI:
10.11005/jbm.2019.26.1.51. PMID:
30899725. PMCID:
PMC6416150.
Article
78. Wang MY, Han ZQ, Gong XW, Li Q, Ma J. 2020; TSH-suppressive therapy can reduce bone mineral density in patients with differentiated thyroid carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 24(2):922–9. DOI:
10.26355/eurrev_202001_20077. PMID:
32016999.
79. Ku EJ, Yoo WS, Lee EK, Ahn HY, Woo SH, Hong JH, et al. 2021; Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis. J Clin Endocrinol Metab. 106(12):3655–67. DOI:
10.1210/clinem/dgab539. PMID:
34302730.
Article
80. Kwak D, Ha J, Won Y, Kwon Y, Park S. 2021; Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 11(5):e043007. DOI:
10.1136/bmjopen-2020-043007. PMID:
33986046. PMCID:
PMC8126273.
Article
81. Fujiyama K, Kiriyama T, Ito M, Kimura H, Ashizawa K, Tsuruta M, et al. 1995; Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. Thyroid. 5(1):13–7. DOI:
10.1089/thy.1995.5.13. PMID:
7787427.
Article
82. Heijckmann AC, Huijberts MS, Geusens P, de Vries J, Menheere PP, Wolffenbuttel BH. 2005; Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol. 153(1):23–9. DOI:
10.1530/eje.1.01933. PMID:
15994742.
Article
83. Reverter JL, Colomé E, Holgado S, Aguilera E, Soldevila B, Mateo L, et al. 2010; Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma. Endocrine. 37(3):467–72. DOI:
10.1007/s12020-010-9339-z. PMID:
20960170.
Article
84. Vera L, Gay S, Campomenosi C, Paolino S, Pera G, Monti E, et al. 2016; Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. Endokrynol Pol. 67(4):350–8. DOI:
10.5603/EP.a2016.0046. PMID:
27387240.
Article
85. Mazziotti G, Formenti AM, Frara S, Olivetti R, Banfi G, Memo M, et al. 2018; High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. J Clin Endocrinol Metab. 103(3):956–64. DOI:
10.1210/jc.2017-01986. PMID:
29121201.
Article
86. Lin SY, Lin CL, Chen HT, Kao CH. 2018; Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr Med Res Opin. 34(5):805–12. DOI:
10.1080/03007995.2017.1378174. PMID:
28884595.
Article
87. Shin DW, Suh B, Lim H, Yun JM, Song SO, Park Y. 2018; J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study. J Bone Miner Res. 33(6):1037–43. DOI:
10.1002/jbmr.3407. PMID:
29447437.
Article
88. Bin-Hong D, Fu-Man D, Yu L, Xu-Ping W, Bing-Feng B. 2020; Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy. Endokrynol Pol. 71(1):15–20. DOI:
10.5603/EP.a2019.0049. PMID:
31681976.
Article
89. Lee MY, Park JH, Bae KS, Jee YG, Ko AN, Han YJ, et al. 2014; Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer. Ann Surg Treat Res. 86(2):55–60. DOI:
10.4174/astr.2014.86.2.55. PMID:
24761409. PMCID:
PMC3994597.
Article
90. Moon JH, Kim KM, Oh TJ, Choi SH, Lim S, Park YJ, et al. 2017; The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 102(1):78–85. DOI:
10.1210/jc.2016-2740. PMID:
27754806.
91. De Mingo Dominguez ML, Guadalix Iglesias S, Martin-Arriscado Arroba C, Lopez Alvarez B, Martinez Diaz-Guerra G, Martinez-Pueyo JI, et al. 2018; Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. Endocrine. 62(1):166–73. DOI:
10.1007/s12020-018-1671-8. PMID:
30014437.
Article
92. Hawkins Carranza F, Guadalix Iglesias S, Luisa De Mingo Dominguez M, Martin-Arriscado Arroba C, Lopez Alvarez B, Allo Miguel G, et al. 2020; Trabecular bone deterioration in differentiated thyroid cancer: impact of long-term TSH suppressive therapy. Cancer Med. 9(16):5746–55. DOI:
10.1002/cam4.3200. PMID:
32583973. PMCID:
PMC7433843.
Article
93. Moon JH, Jung KY, Kim KM, Choi SH, Lim S, Park YJ, et al. 2016; The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma. Bone. 83:104–10. DOI:
10.1016/j.bone.2015.10.015. PMID:
26518742.
Article
94. Tournis S, Antoniou JD, Liakou CG, Christodoulou J, Papakitsou E, Galanos A, et al. 2015; Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol (Oxf). 82(2):197–204. DOI:
10.1111/cen.12560. PMID:
25040693.
Article
95. Kim K, Kim IJ, Pak K, Kim SJ, Shin S, Kim BH, et al. 2018; Evaluation of bone mineral density using DXA and cQCT in postmenopausal patients under thyrotropin suppressive therapy. J Clin Endocrinol Metab. 103(11):4232–40. DOI:
10.1210/jc.2017-02704. PMID:
29982711.
Article
96. Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, et al. 2009; Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. Thyroid. 19(5):437–42. DOI:
10.1089/thy.2008.0428. PMID:
19415993.
Article
97. Panebianco P, Rosso D, Destro G, Scarpinato RA, Tropea S, Rizzo A, et al. 1997; Use of disphosphonates in the treatment of osteoporosis in thyroidectomized patients on levothyroxin replacement therapy. Arch Gerontol Geriatr. 25(2):219–25. DOI:
10.1016/S0167-4943(97)00013-7. PMID:
18653109.
Article
98. Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. 2008; Hypoparathyroidism after total thyroidectomy: a prospective study. Arch Surg. 143(2):132–7. discussion 8DOI:
10.1001/archsurg.2007.55. PMID:
18283137.
99. Pattou F, Combemale F, Fabre S, Carnaille B, Decoulx M, Wemeau JL, et al. 1998; Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg. 22(7):718–24. DOI:
10.1007/s002689900459. PMID:
9606288.
Article
100. Roher HD, Goretzki PE, Hellmann P, Witte J. 1999; Complications in thyroid surgery. Incidence and therapy. Chirurg. 70(9):999–1010. DOI:
10.1007/s001040050757. PMID:
10501664.
101. Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. 2003; The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery. 133(2):180–5. DOI:
10.1067/msy.2003.61. PMID:
12605179.
Article
102. Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, et al. 2000; Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg. 24(11):1335–41. DOI:
10.1007/s002680010221. PMID:
11038203.
Article
103. Testini M, Gurrado A, Lissidini G, Nacchiero M. 2007; Hypoparathyroidism after total thyroidectomy. Minerva Chir. 62(5):409–15. DOI:
10.1001/archsurg.2007.44. PMID:
17947951.
104. Kakava K, Tournis S, Papadakis G, Karelas I, Stampouloglou P, Kassi E, et al. 2016; Postsurgical hypoparathyroidism: a systematic review. In Vivo. 30(3):171–9. DOI:
10.1007/s12020-019-01858-4. PMID:
27107072.
105. Silva B, Kousteni S. Bilezikian J, editor. Cellular actions of PTH: osteoblasts, osteoclasts, and osteocytes. The parathyroids. 3rd ed. San Diego: Elsevier Inc.;2015. p. 127–37. DOI:
10.1016/B978-0-12-397166-1.00008-4.
106. Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, et al. 2008; Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 23(12):2018–24. DOI:
10.1359/jbmr.080803. PMID:
18684087. PMCID:
PMC2686925.
Article
108. Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC. 2003; Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 88(7):3155–9. DOI:
10.1210/jc.2002-021388. PMID:
12843159.
Article
109. Amrein K, Dimai HP, Dobnig H, Fahrleitner-Pammer A. 2011; Low bone turnover and increase of bone mineral density in a premenopausal woman with postoperative hypoparathyroidism and thyroxine suppressive therapy. Osteoporos Int. 22(11):2903–5. DOI:
10.1007/s00198-010-1441-9. PMID:
20959964.
Article
110. Takamura Y, Miyauchi A, Yabuta T, Kihara M, Ito Y, Miya A. 2013; Attenuation of postmenopausal bone loss in patients with transient hypoparathyroidism after total thyroidectomy. World J Surg. 37(12):2860–5. DOI:
10.1007/s00268-013-2207-2. PMID:
24045966.
Article
111. Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, et al. 2015; European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 173(2):G1–20. DOI:
10.1530/EJE-15-0628. PMID:
26160136.
Article
112. Orloff LA, Wiseman SM, Bernet VJ, Fahey TJ 3rd, Shaha AR, Shindo ML, et al. 2018; American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid. 28(7):830–41. DOI:
10.1089/thy.2017.0309. PMID:
29848235.
Article